IBM (NYSE: IBM) and the New York Genome Center have partnered to evaluate the Watson supercomputer’s cognitive system for a genomic research project intended to help clinicians develop treatment methods for cancer patients.
NYGC and its medical partners will develop a personalized care for patients with glioblastoma, a type of brain cancer, by using IBM’s Watson tool, IBM said Wednesday.
The company and center aim to help oncologists identify genome sequencing patterns and correlate medical data from journals, new research and clinical records in order to treat patients.
John Kelly III, senior vice president and director of IBM Research, said the company intends for doctors to “attack cancer and other devastating diseases with treatments that are tailored to the patient’s and disease’s own DNA profiles.”
Clinicians will examine treatment options for adaptation to the patient’s genetic mutations, IBM says.
The Watson system will also work to analyze genetic data and biomedical databases.